Abstract
Purpose
The benefit of whole brain radiotherapy (WBRT) for late stage breast cancer patients with brain metastases has been questioned. In this study we evaluated survival and level of care (hospital or home) following WBRT in a population-based cohort by personal and tumor characteristics.
Methods
We identified 241 consecutive patients with breast cancer and brain metastases receiving WBRT in Stockholm, Sweden, 1999–2012. Through review of medical records, we collected data on prognostic determinants including level of care before and after WBRT. Survival was estimated using Cox regression, and odds ratios (OR) of not coming home using logistic regression.
Results
Median age at WBRT was 58 years (range 30--–88 years). Most patients (n = 212, 88%) were treated with 4 Gray × 5. Median survival following WBRT was 2.9 months (interquartile range 1.1–6.6 months), and 57 patients (24%) were never discharged from hospital. Poor performance status and triple-negative tumors were associated with short survival (WHO 3–4 median survival 0.9 months, HR = 5.96 (3.88–9.17) versus WHO 0–1; triple-negative tumors median survival 2.0 months, HR = 1.87 (1.23–2.84) versus Luminal A). Poor performance status and being hospitalized before WBRT were associated with increased ORs of not coming home whereas cohabitation with children at home was protective.
Conclusion
Survival was short following WBRT, and one in four breast cancer patients with brain metastases could never be discharged from hospital. When deciding about WBRT, WHO score, level of care before WBRT, and the patient’s choice of level of care in the end-of-life period should be considered.
Electronic supplementary material
The online version of this article (doi:10.1007/s10549-017-4466-3) contains supplementary material, which is available to authorized users.
Keywords: Breast cancer, Brain metastases, Whole brain radiotherapy, Level of care
Introduction
Among patients diagnosed with breast cancer, 5–10% have been reported to develop brain metastases [1, 2]. The occurrence of brain metastases in breast cancer patients is believed to have increased over time [3, 4], and HER2-positive and triple-negative breast cancers are associated with an increased risk [5]. The prognosis of breast cancer patients with brain metastases is poor. Overall survival from diagnosis of brain metastases varies from a few months up to a few years in previous studies [5]. Tumor subtype, performance status, age, and the presence or absence of other distant metastases have been identified as prognostic factors [6].
Patients with limited brain metastases may be treated with surgery, and sometimes followed by adjuvant radiation therapy, or with stereotactic radiotherapy [7–9]. Scoring systems have been developed to predict the prognosis for patients with brain metastases such as the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA), graded prognostic assessment (GPA), and diagnosis-specific GPA. These prognostic scores [10] provide useful tools in choosing intensive treatments in patients with good prognosis or to identify patients with poor prognosis in order to avoid overtreatment. In recent years, the use of whole brain radiotherapy (WBRT) has decreased due to the development of localized treatment options as well as due to concerns about late toxicity of WBRT. Still, WBRT remains the treatment of choice in patients with poor prognosis, widely spread brain metastases, lower performance status, and uncontrolled systemic disease, the goal being symptom control [11].
If WBRT is initiated in late palliative stages it also affects the level of care in the end-of-life period, including the patient´s possibility to choose level of care. Deaths in hospital are common among cancer patients in Western countries, despite the fact that their home is the most frequent preferred place for dying [12, 13]. Therefore, we studied the survival as well as the level of care in a population-based sample of 241 breast cancer patients with brain metastases before and after WBRT.
Methods
Study population and patient characteristics
We identified 281 consecutive patients with intracranial metastases due to breast cancer treated with WBRT at the Karolinska University hospital and Södersjukhuset in Stockholm, Sweden, 1999–2012. Health care in Sweden is tax funded and specialized care in oncology is accessible to all residents. The patients had metastases in the cerebrum, cerebellum, or the leptomeninges. Patients with other cancer diagnoses (n = 5), metastases in the scalp only (n = 18) or who received radiotherapy in an adjuvant setting following surgery of metastases (n = 10) were excluded. The final cohort included 241 patients with breast cancer and brain metastases. Through a detailed review of medical records, we collected data on clinical factors from the primary breast cancer including date of primary diagnosis, tumor subtype, HER2-status, ER-status, TNM-status, and stage. Tumor subtypes was classified as Basal or Triple Negative (ER/PR/HER2 negative), Luminal A (ER/PR positive, HER2 negative), Luminal B (ER/PR/HER2 positive), and HER2 type (ER/PR negative, HER2 positive). We also noted information on neoadjuvant/adjuvant treatment, date and local of first metastases (if not brain), type and number of palliative treatment lines preceding brain metastases (counting each type of administered chemotherapy as one line), the date of diagnosis of brain metastases, and locations of other metastases (visceral, non-visceral or both) at this time. Visceral metastases were defined as lung or liver metastases and non-visceral metastases as bone, skin, or loco-regional spread. We further noted the date of initiation of WBRT, performance status and level of care (home, hospital or hospice) the week before WBRT, administered dose of radiation in Gray (Gy), and family situation (cohabitation and children living at home).
Outcome information
The main outcome was date of death of any cause. The secondary outcome was if the patient was unable to come home after the treatment.
Statistical analyses
We estimated the median survival time from the initation of WBRT, with interquartile range. We used Cox proportional hazards models to estimate and compare time to death by patient- and tumor characteristics with hazard ratios (HR) and 95% confidence intervals (CI). In multivariable analyses, we adjusted for age at WBRT in 10-year intervals and calendar period of WBRT in 3-year intervals. In a second multivariable model, we also adjusted for performance status. The proportional hazards assumption was formally tested based on the Schoenfeld residuals obtained from the Cox model and found to be satisfied.
An unconditional logistic regression model was used to identify risk factors for not ever coming home using odds ratios (OR) and 95% CI. This model was first adjusted for age at WBRT in 10-year intervals and calendar period of WBRT in 3 year intervals, and second for performance status.
The SAS software, Version 9.4 of the SAS System for Windows. Copyright © 2002–2012 SAS Institute Inc was used for all analyses.
Results
Clinical characteristics of the cohort
The median age at WBRT was 58 years (range 30–88 years) (Table 1). At diagnosis of brain metastases, 60 patients (25%) had brain metastases only and 75% had other distant metastases as well (51 patients (21%) also had visceral metastases, 45 patients (19%) had non-visceral metastases, and 85 patients (35%) had both visceral and non-visceral metastases). Median number of palliative chemotherapy lines before WBRT was 2 (range 0–9). Eighty-two patients (34%) had palliative endocrine therapy before WBRT and 150 patients (62%) had not. Palliative trastuzumab had been given before WBRT to 60 patients (25%).
Table 1.
Breast cancer patients with brain metastases treated with whole brain radiotherapy, 1999–2012 (total N = 241)
| Characteristics | Patients | % |
|---|---|---|
| At the time of WBRT | N | |
| Age (years) | ||
| 30–49 | 67 | 28 |
| 50–69 | 137 | 57 |
| 70+ | 37 | 15 |
| Median (range) | 58 (30–88) | |
| Calendar year | ||
| 1999–2001 | 38 | 16 |
| 2002–2004 | 29 | 12 |
| 2005–2007 | 47 | 19 |
| 2008–2010 | 74 | 31 |
| 2011–2012 | 53 | 22 |
| No of brain metastases | ||
| 1–3 (size 5–55 mm) | 33 | 14 |
| 4–6 | 26 | 11 |
| 7–9 | 11 | 5 |
| Massive | 116 | 48 |
| Leptomeningeal | 53 | 22 |
| Missing | 2 | 1 |
| Time between diagnosis of breast cancer and WBRT | ||
| 0–3 years | 94 | 9 |
| 3–6 years | 72 | 30 |
| >6 years | 75 | 31 |
| WBRT dose | ||
| 4 Gy × 5 | 212 | 88 |
| 3 Gy × 10 | 27 | 12 |
| 2 Gy × 20 | 1 | 0 |
| Missing | 1 | 0 |
| WBRT completion | ||
| Yes | 228 | 95 |
| No | 13 | 5 |
| Other metastases | ||
| Only brain | 60 | 25 |
| Brain + viscerala | 51 | 21 |
| Brain + non visceralb | 45 | 19 |
| Brain + multiple | 85 | 35 |
| WHO performance status score | ||
| 0–1 | 128 | 53 |
| 2 | 71 | 29 |
| 3–4 | 41 | 17 |
| Missing | 1 | 0 |
| Family situation | ||
| Married/cohabitation | 96 | 40 |
| Married/cohabitation, w/children | 70 | 29 |
| Alone, w/children | 12 | 5 |
| Alone | 62 | 26 |
| Missing | 1 | 0 |
| Level of care (1 week before WBRT) | ||
| Home | 145 | 60 |
| Hospital | 88 | 37 |
| Palliative inpatient care | 8 | 3 |
| At primary breast cancer diagnosis | ||
| Stage | ||
| 1 | 44 | 21 |
| 2 | 108 | 50 |
| 3 | 40 | 19 |
| 4 | 22 | 10 |
| ER | ||
| ER+ | 135 | 56 |
| ER− | 104 | 43 |
| Missing ER | 2 | 1 |
| HER2 | ||
| HER2+ | 79 | 33 |
| HER2− | 110 | 46 |
| Missing HER2 | 52 | 22 |
| Subtype | ||
| Luminal A | 65 | 27 |
| Luminal B | 36 | 15 |
| HER2 type | 43 | 18 |
| Triple negative | 45 | 19 |
| Missing | 52 | 22 |
| Palliative treatments before WBRT | ||
| No of palliative chemotherapy regimens | ||
| Median (range) | 2 (0–9) | |
| Missing | 5 | 2 |
| Palliative endocrine therapy | ||
| No | 150 | 62 |
| Yes | 82 | 34 |
| Palliative trastuzumab | ||
| No | 172 | 71 |
| Yes | 60 | 25 |
| Missing | 9 | 4 |
aLung and/or liver metastases
bSkin, loco-regional and/or bone metastases
Brain metastases and WBRT
At the time of WBRT, about half of the patients (n = 116, 48%) had massive metastatic spread to the brain, whereas 33 patients (14%) had 1–3 metastases, 26 (11%) had 4–6 metastases, 11 (5%) had 7–9 metastases, and 53 (22%) had leptomeningeal metastases. Most of the patients (n = 212, 88%) were treated with 4 Gy × 5 and 27 (12%) with 3 Gy × 10 and all patients had concomitant steroids. The patients that received 3 Gy × 10 were mostly treated during the early study period (1999–2006). Prior to WBRT, 17 (7%) of the patients had received stereotactic radiotherapy for their brain metastases, 7 (3%) had surgery, and 8 (3%) had both. Thirteen patients (5%) started but could not complete the WBRT. When treatment with WBRT was decided, 129 patients (53%) had WHO performance status score 0–1, whereas 71 (29%) were symptomatic with WHO score 2 and 41 (17%) with WHO score 3–4. In all, 96 (40%) patients were in hospital, whereas 146 (60%) were at home. (Table 1).
Overall survival
Median survival following WBRT was 2.9 months (interquartile range 1.1–6.6 months) (Fig. 1). Performance status was the strongest predictor of survival. Patients with WHO score 2 survived median 2.0 months counting from the first day of WBRT and were at a close to threefold increased rate of death (HR = 2.78, 95% CI 2.01–3.84) and patients with WHO score 3–4 survived less than one (0.9) month corresponding to a sixfold increased rate (HR = 5.96, 3.88–9.17) compared with patients with good performance (WHO score 0–1) (Online Resource 1). Age above 50 years as well as being hospitalized before WBRT was associated with higher mortality before but not after adjustment for performance status (Online Resource 2). Mortality was significantly higher if the patients were treated with WBRT in the first calendar period under study, 1999–2001, compared to later periods.
Fig. 1.
Survival after WBRT for breast cancer patients with brain metastases, in Stockholm, Sweden 1999–2012
If the time interval was short (0–3 years) between the primary breast cancer diagnosis and WBRT, mortality following WBRT was significantly higher than if a longer time had passed (3–6 years or more than 6 years). Similarly, mortality was significantly higher if the patients had not been treated with palliative trastuzumab or palliative chemotherapy regimens before WBRT. With respect to the primary breast cancer, triple negative/basal like (HER2 negative, ER negative) and HER2 type (HER2 positive, ER negative) breast cancers were common in this cohort, 45 (19%) and 43 (18%) patients, respectively (Table 1). Whereas primary breast cancer stage and HER2-status did not significantly affect survival following WBRT, ER negative as well as triple-negative tumor status were associated with high mortality (Table 2).
Table 2.
Survival following whole brain radiotherapy among women with breast cancer and brain metastases, 1999–2012
| Characteristics | Median survival months (range) | Adjusted HRa
(95% CI) |
Adjusted HRb
(95% CI) |
|---|---|---|---|
| At the time of WBRT | |||
| Age (years) | |||
| 30–49 | 4.1 (0.2–86.8) | 1.0 (ref) | 1.0 (ref) |
| 50–69 | 2.6 (0–40.6) | 1.36 (1.01–1.84) | 1.13 (0.83–1.54) |
| 70+ | 2.3 (0.1–32.6) | 1.73 (1.15–2.60) | 1.28 (0.84–1.94) |
| Calendar year | |||
| 1999–2001 | 1.6 (0.17–32.6) | 1.85 (1.20–2.86) | 1.91 (1.23–2.96) |
| 2002–2004 | 4.8 (0.4–86.8) | 1.07 (0.67–1.71) | 1.06 (0.66–1.70) |
| 2005–2007 | 3.0 (0–23.0) | 1.26 (0.85–1.88) | 1.32 (0.88–1.97) |
| 2008–2010 | 3.1 (0.1–41.1) | 1.25 (0.87–1.80) | 1.15 (0.80–1.67) |
| 2011–2012 | 2.8 (0.1–35.4) | 1.0 (ref) | 1.0 (ref) |
| No of brain metastases | |||
| 1–3 (Size 5–55 mm) | 2.5 (0.2–36.2) | 1.04 (0.67–1.64) | 1.08 (0.68–1.72) |
| 4–6 | 2.5 (0.3–11.8) | 1.33 (0.82–2.15) | 1.60 (0.98–2.62) |
| 7–9 | 3.1 (0.6–12.4) | 1.22 (0.63–2.38) | 1.46 (0.74–2.88) |
| Massive | 3.0 (0.1–86.8) | 0.94 (0.67–1.33) | 1.13 (0.80–1.60) |
| Leptomeningeal | 2.5 (0–35.4) | 1.0 (ref) | 1.0 (ref) |
| Time between diagnosis and WBRT | |||
| 0–3 years | 2.1 (0–36.2) | 1.62 (1.17–2.24) | 1.51 (1.09–2.10) |
| 3–6 years | 3.5 (0.2–41.1) | 1.47 (1.04–2.08) | 1.24 (0.88–1.76) |
| >6 years | 3.6 (0.1–86.8) | 1.0 (ref) | 1.0 (ref) |
| WBRT dose | |||
| 4 Gy × 5 | 2.6 (0–86.8) | 1.0 (ref) | 1.0 (ref) |
| 3 Gy × 10 | 4.1 (0.2–32.6) | 0.73 (0.47–1.13) | 0.73 (0.47–1.14) |
| Other metastases | |||
| Only brain | 3.7 (0–86.8) | 1.0 (ref) | 1.0 (ref) |
| Brain + visceralc | 2.8 (0.1–21.6) | 1.16 (0.78–1–71) | 1.11 (0.74–1.67) |
| Brain + non viscerald | 4.1 (0.1–32.6) | 0.96 (0.64–1.43) | 1.04 (0.70–1.56) |
| Brain + multiple | 2.5 (0.13–41.1) | 1.59 (1.11–2.27) | 1.37 (0.96–1.94) |
| WHO performance status score | |||
| 0–1 | 5.5 (0.4–86.8) | 1.0 (ref) | –– |
| 2 | 2.0 (0.1–16.5) | 2.78 (2.01–3.84) | |
| 3–4 | 0.9 (0–5.5) | 5.96 (3.88–9.17) | |
| Family situation | |||
| Married/cohabitation | 2.4 (0.1–32.6) | 1.22 (0.87–1.73) | 1.34 (0.95–1.88) |
| Married/cohabitation w/children | 3.2 (0–86.8) | 1.11 (0.73–1.70) | 1.06 (0.69–1.62) |
| Alone w/children | 8.2 (0.2–41.1) | 0.64 (0.33–1.25) | 0.85 (0.43–1.68) |
| Alone | 3.1 (0.1–40.6) | 1.0 (ref) | 1.0 (ref) |
| Level of care (one week before WBRT) | |||
| Home | 4.1 (0.1–86.8) | 1.0 (ref) | 1.0 (ref) |
| Hospital | 2.0 (0–40.6) | 1.53 (1.16–2.04) | 1.03 (0.75–1.40) |
| Palliative inpatient care | 2.5 (0.3–3.7) | 2.60 (1.24–5.45) | 1.11 (0.51–2.42) |
| At primary breast cancer diagnosis | |||
| Stage | |||
| 1 | 4.0 (0.1–86.8) | 1.0 (ref) | 1.0 (ref) |
| 2 | 2.5 (0–40.6) | 1.21 (0.84–1.73) | 1.18 (0.81–1.70) |
| 3 | 2.6 (0.2–41.1) | 1.40 (0.90–2.18) | 1.52 (0.97–2.37) |
| 4 | 1.6 (0.3–21.6) | 1.62 (0.96–2.76) | 1.38 (0.81–2.37) |
| ER | |||
| ER+ | 3.4 (0–86–8) | 1.0(ref) | 1.0 (ref) |
| ER− | 2.6 (0.2–35.4) | 1.35 (1.03–1.77) | 1.33 (1.01–1.77) |
| HER2 | |||
| HER2+ | 4.2 (0.1–86.8) | 1.0 (ref) | 1.0 (ref) |
| HER2− | 2.5 (0–41.1) | 1.28 (0.94–1.75) | 1.27 (0.92–1.75) |
| Subtype | |||
| Luminal A | 3.5 (0–41.1) | 1.0 (ref) | 1.0 (ref) |
| Luminal B | 3.9 (0.1–86.8) | 0.94 (0.62–1.44) | 0.99 (0.64–1.52) |
| HER2 type | 4.1 (0.2–21.6) | 1.04 (0.68–1.57) | 1.04 (0.68–1.61) |
| Triple negative | 2.0 (0.2–35.4) | 1.87 (1.25–2.80) | 1.87 (1.23–2.84) |
| Palliative treatments before WBRT | |||
| Palliative trastuzumab | |||
| Yes | 5.0 (0.1–86.8) | 1.0 (ref) | 1.0 (ref) |
| No | 2.4 (0–41.1) | 1.40 (1.03–1.90) | 1.37 (1.01–1.86) |
| No of palliative chemotherapy regimens | |||
| 0 | 1.6 (0–40.6) | 1.0 (ref) | 1.0 (ref) |
| 1+ | 3.5 (0.1–86.8) | 0.61 (0.44–0.85) | 0.65 (0.46–0.92) |
Statistically significant results are marked in bold
aadjusted for age at WBRT (in 10-year intervals) and calendar period of WBRT (in 3-year intervals)
badjusted for WHO performance status score, age at WBRT (in-10 year intervals) and calendar period of WBRT (in 3-year intervals)
cLung and/or liver metastases
dSkin, loco-regional, and/or bone metastases
Level of care after WBRT
Fifty-seven patients (24%) were never discharged from hospital following WBRT (Table 3). The median survival in this group was 1.1 month (interquartile range 0.5-2.1 months). Among the patients that were hospitalized before WBRT, 45 (47%) did not come home again, whereas this was true for 12 patients (8%) among those who were at home before WBRT (p < 0.0001). Among patients with WHO 0–1 before WBRT, 124 (97%) came home again, whereas if WHO was 2, 46 (65%) patients came home, and if the WHO was 3–4, 14 (34%) came home (p < 0.0001). In the first logistic regression model adjusting only for age and calendar period, poor performance status was most strongly associated with not coming home (Table 4). Other associated factors included triple-negative tumor status, short duration between primary breast cancer diagnosis and WBRT, few palliative chemotherapy lines, inpatient care before WBRT as well as high age at diagnosis (70+ years, adjusting only for calendar period). With additional adjustment for performance status, hospital or palliative inpatient care the week before WBRT remained significantly associated with not coming home after WBRT. Also, living with a partner and children at home emerged as a protective factor for not coming home (Table 4).
Table 3.
Patients coming home or not after WBRT by level of care and performance status before
| Ever at home after WBRT | Total | ||
|---|---|---|---|
| Yes | No | ||
| Total | 184 (76) | 57 (24) | 241 (100%) |
| Level of care before WBRT | |||
| Home | 133 (92%) | 12 (8%) | 145 (100%) |
| Hospital/Palliative inpatient care | 51 (53%) | 45 (47%) | 96 (100%) |
| WHO performance status score one week before WBRT | |||
| 0–1 | 124 (97%) | 4 (3%) | 128 (100%) |
| 2 | 46 (65%) | 25 (35%) | 71 (100%) |
| 3–4 | 14 (34%) | 27 (66%) | 41 (100%) |
Table 4.
The relative risk of not coming home following WBRT by patient and tumor characteristics
| Characteristics | N (%) of patients not coming home | Adjusted ORa (95% CI) | Adjusted ORb (95% CI) |
|---|---|---|---|
| At the time of WBRT | |||
| Age (years) | |||
| 30–49 | 6 (9) | 1.0 (ref) | 1.0 (ref) |
| 50–69 | 37 (27) | 3.76 (1.48–9.53) | 2.60 (0.84–8.08) |
| 70+ | 14 (38) | 6.45 (2.16–19.2) | 3.36 (0.91–13.18) |
| Calendar year | |||
| 1999–2006 | 21 (21) | 1.0 (ref) | 1.0 (ref) |
| 2007–2012 | 36 (26) | 1.06 (0.55–2.03) | 1.07 (0.49–2.38) |
| No of brain metastases | |||
| 1–3 (Size 5–55 mm) | 8 (24) | 1.0 (ref) | 1.0 (ref) |
| 4–6 | 8 (30) | 1.72 (0.48–6.12) | 2.44 (0.50–12.1) |
| 7–9 | 2 (18) | 0.73 (0.13–4.56) | 1.40 (0.18–11.0) |
| Massive | 26 (22) | 1.19 (0.43–3.27) | 1.57 (0.47–5.18) |
| Leptomeningeal | 13 (25) | 1.26 (0.42–3.80) | 1.21 (0.33–4.37) |
| Time between diagnosis and WBRT | |||
| 0–3 years | 30 (32) | 1.0 (ref) | 1.0 (ref) |
| 3–6 years | 12 (17) | 0.45 (0.20–1.00) | 0.54 (0.20–1.44) |
| >6 years | 15 (20) | 0.43 (0.20–0.93) | 0.47 (0.19–1.17) |
| WBRT dose | |||
| 4 Gy × 5 | 51 (24) | 1.0 (ref) | 1.0 (ref) |
| 3 Gy × 10 | 6 (22) | 1.19 (0.43–2.30) | 1.54 (0.43–5.46) |
| Other metastases | |||
| Only brain | 14 (23) | 1.0 (ref) | 1.0 (ref) |
| Brain + visceralc | 9 (18) | 0.75 (0.27–2.03) | 0.66 (0.20–2.21) |
| Brain + non viscerald | 11 (24) | 1.20 (0.46–3.11) | 1.82 (0.53–6.24) |
| Brain + multiple | 23 (27) | 1.85 (0.80–4.26) | 1.24 (0.46–3.34) |
| WHO performance status score | |||
| 0–1 | 4 (3) | 1.0 (ref) | – |
| 2 | 25 (35) | 16.9 (5.39–53.1) | – |
| 3–4 | 27 (66) | 54.5 (15.7–189) | – |
| Family situation | |||
| Married/cohabitation | 25 (26) | 0.63 (0.30–1–31) | 0.54 (0.22–1.37) |
| Married/cohabitation w/children | 8 (11) | 0.38 (0.13–1–09) | 0.21 (0.06–0.78) |
| Alone w/children | 1(8) | 0.22 (0.02–1.97) | 1.27 (0.11–14.97) |
| Alone | 23 (37) | 1.0 (ref) | 1.0 (ref) |
| Level of care (1 week before WBRT) | |||
| Home | 12 (8) | 1.0 (ref) | 1.0 (ref) |
| Hospital | 40 (45) | 10.2 (4.63–22.4) | 5.20 (2.12–12.7) |
| Palliative inpatient care | 4 (63) | 21.2 (4.03–111) | 5.27 (0.89–31.06) |
| At primary breast cancer diagnosis | |||
| ER | |||
| ER+ | 31 (23) | 1.0 (ref) | 1.0 (ref) |
| ER− | 26 (25) | 1.11 (0.57–2.14) | 1.19 (0.52–2.74) |
| HER2 | |||
| HER2+ | 14 (18) | 1.0 (ref) | 1.0 (ref) |
| HER2− | 31 (28) | 2.04 (0.93–4.49) | 1.97 (0.70–5.54) |
| Subtype | |||
| Luminal A | 12 (18) | 1.0 (ref) | 1.0 (ref) |
| Luminal B | 10 (28) | 1.69 (0.60–4.80) | 2.66 (0.66–10.72) |
| HER2 type | 4 (9) | 0.36 (0.10–1.30) | 0.39 (0.09–1.80) |
| Triple negative | 19 (42) | 2.57 (1.02–6.50) | 2.85 (0.89–9.15) |
| Palliative treatments before WBRT | |||
| Palliative trastuzumab | |||
| Yes | 10 (17) | 0.63 (0.28–1.40) | 0.68 (0.25–1.90) |
| No | 46 (27) | 1.0 (ref) | 1.0 (ref) |
| No of palliative chemotherapy regimens | |||
| 0 | 22 (42) | 1.0 (ref) | 1.0 (ref) |
| 1+ | 35 (19) | 0.42 (20–0.85) | 0.50 (0.21–1.19) |
Statistically significant results are marked in bold
aAdjusted for age at WBRT (in 10-year intervals) and calendar period of WBRT (in 3-year intervals)
bAdjusted for WHO performance status score, age at WBRT (in 10-year intervals) and calendar period of WBRT (in 3-year intervals
cLung and/or liver metastases
dSkin, loco-regional and/or bone metastases
Discussion
In this population-based study of consecutive breast cancer patients with brain metastases treated with WBRT, median survival was short, less than 3 months counting from the start of WBRT, and one in four patients could not be discharged from hospital following radiotherapy. As expected, we observed a significant association between triple-negative tumors, poor performance status, and short survival. Patients with WHO score 3–4 had a short median survival of less than 1 month and two-thirds of these patients were not able to come home again. The risk of not coming home again was affected not only by performance status, but also by the level of care the week before treatment with WBRT and to some extent by family situation (if the patient was living with a partner with children at home or not). Given the delayed effect of radiotherapy, our results support that hospitalized patients with poor performance status and short expected survival may benefit more from abstaining from WBRT rather than receiving it.
Patients with limited brain metastases may be treated with surgery, sometimes followed by adjuvant radiation therapy or with stereotactic radiotherapy [7–9]. For patients with a single, large metastasis in a surgically accessible location, resection may still be the best choice for control of symptoms and prognosis. Surgery is also used in some patients with a limited number of metastases. Randomized clinical trials that have compared surgery plus WBRT to WBRT alone in patients with a single brain metastasis, have shown a survival benefit for the combined approach [14–16]. Stereotactic radiosurgery is recommended to patients who are inoperable with 4–5 metastases at most (of diameter 3 cm or less) and with few or no symptoms. In light of these developments of localized treatment, the use of WBRT as only treatment has decreased. Still, WBRT remains the treatment of choice in patients with poor prognosis, widely spread brain metastases, lower performance status, and uncontrolled systemic disease, the goal being symptom control and improvement of neurological deficits [11]. At the same time, the risk of overtreatment is particularly present among these poor prognosis patients [10]. Earlier studies have shown that 50–80% of the patients respond with improvement of neurological symptoms after WBRT [17–20]; however, improvements may be first noted a few days or up to a few weeks after WBRT [21]. Also, the duration of an improvement may be short. In one previous study, the median duration of effect was observed to be 3.7 month (range 0.4–11.8 months) [22].
To our knowledge, this is the first study of level of care in brain metastasis patients treated with WBRT. Level of care following treatment is expected to vary not only by patient and disease characteristics and survival but also external factors such as social situation and access to advanced palliative care at home. In spite of easy access to palliative home care in the Stockholm area, we were surprised to note that as many as 25% of all patients in our study could not be discharged from hospital following WBRT. Median survival in our cohort was not shorter (2.9 months from the start of WBRT) than previously reported. Patients with brain metastases of any cancer have been described to have a median survival of 3 to 6 months following diagnosis of brain metastases in two single center studies [23, 24]. In a recent observational study from two university specialist care centers, local treatment with surgery or stereotactic radiosurgery with or without WBRT was compared with WBRT alone in breast cancer patients with brain metastases (single or multiple). Among the 116 patients in the study, 50 patients were treated with WBRT alone, and the overall survival was median 5.7 months after brain metastases diagnosis in this group (95% CI 0.5–11 months) [25]. Since we counted survival from the start of WBRT it is expected that we report shorter survival. The patients in our study lived in the Stockholm area, geographically close to the hospital radiotherapy departments. The relatively easy access could have resulted in a broader use of WBRT compared to other centers, i.e., including patients who might have been judged unfit under different conditions, potentially lowering the survival in our cohort. On the other hand, previous specialist single center studies may have included more selected patient groups in comparison to our population-based assessment.
As expected, poor performance status and a triple-negative primary breast cancer were associated with dismal outcome following WBRT. Within the breast cancer specific scores (GPA) high age, poor performance status, Karnofsky index less than 50, high number of brain metastases, and a triple-negative primary tumor predict short survival [6, 26]. Level of care before treatment with WBRT was associated with survival when adjusted for age, but not with additional adjustment for performance status. However, the odds ratio for not coming home after WBRT was still significantly higher after adjustment for age and performance status.
Among all breast cancer patients diagnosed in Stockholm in 2014, triple-negative breast cancers constituted 8.2%, the HER2 type 13.8%, and the Luminal A and B types together represented 78.1% [27]. In this study, triple-negative tumors (19%) and HER2 type tumors (18%) cancers were more common.
For breast cancer patients with brain metastases and unfavorable prognostic characteristics as outlined above it would likely be more appropriate in many cases to recommend best supportive care including steroids for symptom control instead of WBRT and discuss goals of care with the patient. Time spent on hospital stays for WBRT would then be spared and treatment side effects would be avoided for patients in late palliative stages if withheld from WBRT. In Western countries deaths in hospital are common among cancer patients, despite the fact that their home is the most frequent preferred place for dying [12, 13]. In an Italian study, researchers sampled 2000 patients who died due to cancer from March 2002 until June 2003. The non-professional caregiver, defined as the person closest to the patient and best informed about the patient’s situation during the last three months of life, was identified and interviewed. The caregivers reported that home was the most preferred place of death for 94% of the cancer patients, with a range between 90 and 99% within the country. In a recent systematic review of worldwide studies of preferred place of death among cancer patients a preference of home deaths was found among 59.9% (range 39.7–100%) on average across all studies. The preferred and actual death places among these studies differed significantly (p < 0.05). The lack of conformance between the patients preferred place of death and where they actually die seems to be the same worldwide [13]. In our study we found that patients living with a partner and children at home were discharged from hospital more often than patients in other family situations. These patients may have a stronger desire to come home and a higher ability to communicate their wishes to health professionals together with family members. A Chinese study from 2015 reported that cancer patients, who live with relatives more often prefer home as death place [28]. Our findings support that when patients with brain metastases due to breast cancer are in late palliative stages, discussions and considerations about the patient’s choice of level of care in the end-of-life period should take place.
The strengths of our study include the population-based identification of all consecutively treated patients in the Stockholm area and the use of prospectively recorded exposure and outcome data from medical records. A limitation was the relatively small number of patients, leading to low precision in some analyses and the sometimes indirect estimation of variables such as WHO performance status score based on the medical record notes.
To summarize, in this clinical study of consecutively treated patients, one in four breast cancer patients with brain metastases could not be discharged from hospital following WBRT. These results suggest some overtreatment of WBRT in late palliative stages and encourages use of existing scores such as the breast cancer specific GPA to help predict prognosis and choose the most optimal treatment and care together with the patient. For patients with poor performance status requiring hospital care and with unfavorable breast cancer subtypes, best supportive care including steroids for symptom control should be considered to avoid hospital stays in the end-of life period. When deciding about WBRT, the patient´s performance status, level of care before WBRT, and importantly also the patient´s choice of care in the end-of-life period should be taken into consideration.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Acknowledgments
Funding
This study was funded by a grant from Bröstcancerföreingens riksorganisation (BRO) in Sweden.
Abbreviations
- WBRT
Whole Brain Radiotherapy
- WHO
World Health Organization
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The study was approved by the Stockholm Regional Research Ethics Board, 2013/295-31/5.
Informed consent
For this type of study formal consent is not required.
Footnotes
Electronic supplementary material
The online version of this article (doi:10.1007/s10549-017-4466-3) contains supplementary material, which is available to authorized users.
References
- 1.Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–3617. doi: 10.1200/JCO.2004.01.175. [DOI] [PubMed] [Google Scholar]
- 2.Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–2872. doi: 10.1200/JCO.2004.12.149. [DOI] [PubMed] [Google Scholar]
- 3.Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13:1648–1655. doi: 10.1158/1078-0432.CCR-06-2478. [DOI] [PubMed] [Google Scholar]
- 4.Frisk G, Svensson T, Backlund LM, et al. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer. 2012;106:1850–1853. doi: 10.1038/bjc.2012.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lin NU, Amiri-Kordestani L, Palmieri D, et al. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19:6404–6418. doi: 10.1158/1078-0432.CCR-13-0790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sperduto PW, Kased N, Roberge D, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol. 2013;112:467–472. doi: 10.1007/s11060-013-1083-9. [DOI] [PubMed] [Google Scholar]
- 7.Liu Y, Alexander BM, Chen YH, et al. Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. J Neurooncol. 2015;124:429–437. doi: 10.1007/s11060-015-1855-5. [DOI] [PubMed] [Google Scholar]
- 8.Bergh (2014) Nationellt vårdprogram för bröstcancer. Nationellt vårdprogram för bröstcancer
- 9.Fontanella C, De Carlo E, Cinausero M, et al. Central nervous system involvement in breast cancer patients: is the therapeutic landscape changing too slowly? Cancer Treat Rev. 2016;46:80–88. doi: 10.1016/j.ctrv.2016.03.014. [DOI] [PubMed] [Google Scholar]
- 10.Nieder C, Norum J, Dalhaug A, et al. Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. Clin Exp Metastasis. 2013;30:723–729. doi: 10.1007/s10585-013-9573-x. [DOI] [PubMed] [Google Scholar]
- 11.Feyer P, Sautter-Bihl ML, Budach W, et al. DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol. 2010;186:63–69. doi: 10.1007/s00066-010-2100-y. [DOI] [PubMed] [Google Scholar]
- 12.Beccaro M, Costantini M, Giorgi Rossi P, et al. Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC) J Epidemiol Community Health. 2006;60:412–416. doi: 10.1136/jech.2005.043646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Nilsson J, Blomberg C, Holgersson G, et al. End-of-life care: where do cancer patients want to die? A systematic review. Asia Pac J Clin Oncol. 2017 doi: 10.1111/ajco.12678. [DOI] [PubMed] [Google Scholar]
- 14.Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500. doi: 10.1056/NEJM199002223220802. [DOI] [PubMed] [Google Scholar]
- 15.Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711–717. doi: 10.1016/0360-3016(94)90558-4. [DOI] [PubMed] [Google Scholar]
- 16.Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470–1476. doi: 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
- 17.Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000;62:211–216. doi: 10.1023/A:1006486423827. [DOI] [PubMed] [Google Scholar]
- 18.Broadbent AM, Hruby G, Tin MM, et al. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol. 2004;71:259–265. doi: 10.1016/j.radonc.2004.02.019. [DOI] [PubMed] [Google Scholar]
- 19.Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1–9. doi: 10.1016/0360-3016(80)90195-9. [DOI] [PubMed] [Google Scholar]
- 20.Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;18(4):CD003869. doi: 10.1002/14651858.CD003869.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Edwards A, Gerard G. The management of cerebral metastases. Eur J Pall Care. 1998;5:7–11. [Google Scholar]
- 22.Ogawa K, Yoshii Y, Nishimaki T, et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol. 2008;86:231–238. doi: 10.1007/s11060-007-9469-1. [DOI] [PubMed] [Google Scholar]
- 23.Hall WA, Djalilian HR, Nussbaum ES, et al. Long-term survival with metastatic cancer to the brain. Med Oncol. 2000;17:279–286. doi: 10.1007/BF02782192. [DOI] [PubMed] [Google Scholar]
- 24.Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78:1781–1788. doi: 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
- 25.Chong JU, Ahn SG, Lee HM, et al. Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes. J Breast Cancer. 2015;18:29–35. doi: 10.4048/jbc.2015.18.1.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol. 2015;33:2239–2245. doi: 10.1200/JCO.2014.58.8517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bröstcancerregistret SFN (2014) Årsrapport RAPPORT FRÅN NATIONELLA BRÖSTCANCERREGISTRET 2014
- 28.Gu X, Cheng W, Cheng M, et al. The preference of place of death and its predictors among terminally ill patients with cancer and their caregivers in China. Am J Hosp Palliat Care. 2015;32:835–840. doi: 10.1177/1049909114542647. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.